{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 75,
  "pageCount": 366,
  "prevPage": 74,
  "nextPage": 76,
  "slideType": "preempt_rebuttal",
  "function": "preempt_rebuttal",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a 'before-after' narrative structure to show that shifting chemical scaffolds did not solve the underlying safety issues in H3 receptor drug development.",
  "elementsJson": [
    "paragraph",
    "screenshot"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/75",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-75",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.42,
        "x": 0.51,
        "y": 0.55
      },
      "kind": "callout",
      "text": "...and same issues with non-imidazole-based compounds like pitolisant",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7be21f8-407e-4af8-bd9a-668a5edbb9c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.42,
        "x": 0.07,
        "y": 0.55
      },
      "kind": "callout",
      "text": "Excerpts from 2009 paper – challenges with imidazole-containing compounds...",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8d53ab9-a0e7-4996-a5e3-bd5e919d4539",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "The literature on the toxicity and pharmacokinetic difficulties of both imidazole and non-imidazole-based H3R candidates is extensive.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9ccf-2229b6fff377",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "At first in the 1990's, every pharma company large and small with an H3 receptor agonist program developed compounds with an imidazole (C3N2H4) ring... By the late 2000's, the field then migrated to non-imidazole-based compounds like pitolisant...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "349ac917-0891-4255-b8f2-b98954fe66c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.42,
        "x": 0.07,
        "y": 0.64
      },
      "kind": "paragraph",
      "text": "The histamine H3 receptor as a therapeutic drug target for CNS disorders... Early H3R antagonists/inverse agonists that reached the clinic were imidazole-containing compounds...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c3f815b-b64a-4991-bb4e-d6331fe69bcb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.42,
        "x": 0.51,
        "y": 0.64
      },
      "kind": "paragraph",
      "text": "Whilst the majority of non-imidazole classes of H3R antagonists appear not to inhibit significantly the CYP family of enzymes, many H3R antagonist programmes have reportedly suffered from significant blockade of the hERG K+ channel...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ace96285-db5a-44b7-a3d5-2641b40bfe78",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“significant blockade of the hERG channel,” “QTc prolongation,” and “drug-drug interactions,” and “phospholipidosis.” — 2009 paper",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9ccf-2692eb13a4d9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.07,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Source: https://pubmed.ncbi.nlm.nih.gov/19429511/",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "523cc47c-8095-4c51-9a6a-55efb2a2951f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "preempt_rebuttal",
      "slug": null,
      "matchId": "8b908ad1-ef0f-4c3e-b710-97bcfbbc4d95",
      "evidence": "The slide systematically addresses potential concerns about drug safety by showing that both historical and newer approaches faced the same failure modes.",
      "confidence": 0.85
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}